The Biotech-Industrial Complex Gets Ready to Define What is Human
By Stuart Newman,
CounterPunch
| 08. 16. 2019
Newly approved human-animal chimera procedures are just some of a number of scientifically and ethically questionable techniques that are being soft-pedaled and normalized on a daily basis.
Fabricating part-human-part-nonhuman animals, with features of both, seemed like something out of Greek mythology until the late 20th century. New research then on “geeps,” fully developed, viable mixtures of goats and sheep, showed that constructing such “chimeras” was a real possibility. Still, the warning by H.G. Wells, a century before, in his novel “The Island of Dr. Moreau,” that scientific experiments like this could go terribly awry, seemed fantastical. But this will soon change. At the end of July, it was reported that the biologist Juan Carlos Izpisúa Belmonte, director of a laboratory at the Salk Institute in California, produced fetal human-monkey chimeras. He did this in collaboration with researchers in China. And this month the Japanese government is expected to give the go-ahead to scientist Hiromitsu Nakauchi, leader of teams at the University of Tokyo and Stanford University in California, to conduct similar experiments with the goal of bringing human-pig chimeras to full term. These novel forms of life will soon be among us.
Dr. Nakauchi acknowledges that the concerns of Wells and later writers like Aldous...
Related Articles
By Bernice Lottering, Gene Online | 11.08.2024
South Africa’s updated health-research ethics guidelines, which now include heritable human genome editing, have sparked concern among scientists. The revisions, made in May but only recently gaining attention, outline protocols for modifying genetic material in sperm, eggs, or embryos—changes...
By Jim Thomas, Scan the Horizon | 11.19.2024
It’s the wee hours of 2nd November 2024 in Cali, Colombia. In a large UN negotiating hall Colombian Environment Minister Susana Muhamed has slammed down the gavel on a decision that should send a jolt through the AI policy world. ...
By Ned Pagliarulo, BioPharmaDive | 11.05.2024
A medicine built around a more precise form of CRISPR gene editing appeared to work as designed in its first clinical trial test, developer Beam Therapeutics said Tuesday. But the death of a trial participant could renew concerns about an older...
By Ruth Retassie, PET | 10.21.2024